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Reactive oxygen speciesNADPH oxidase-4 (Nox4) is an important modulator of redox signaling that is inducible at the level of
transcriptional expression in multiple cell types. By contrast to other Nox enzymes, Nox4 is continuously
active without requiring stimulation. We reported recently that expression of Nox4 is induced in the adult
heart as an adaptive stress response to pathophysiological insult. To elucidate the potential downstream
target(s) regulated by Nox4, we performed amicroarray screen to assess the transcriptomes of transgenic (tg)
mouse hearts in which Nox4 was overexpressed. The screen revealed a signiﬁcant increase in the expression
of many antioxidant and detoxifying genes regulated by Nrf2 in tg compared to wild-type (wt) mouse hearts,
and this ﬁnding was subsequently conﬁrmed by Q-PCR. Expression of glutathione biosynthetic and recycling
enzymes was increased in tg hearts and associated with higher levels of both GSH and the ratio of reduced:
oxidised GSH, compared to wt hearts. The increases in expression of the antioxidant genes and the changes in
glutathione redox effected by Nox4 were ablated in an Nrf2-null genetic background. These data therefore
demonstrate that Nox4 can activate the Nrf2-regulated pathway, and suggest a potential role for Nox4 in the
regulation of GSH redox in cardiomyocytes.otide phosphate; Nrf2, NF-E2-
in reaction; ER, endoplasmic
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The NADPH oxidase family of enzymes (Noxs) produce reactive
oxygen species (ROS) as their primary function, and consequently their
roles in tightly regulated redox signaling pathways are areas of intense
study. The catalytic core of eachNADPHoxidase comprises aNox subunit,
7 members of which have been identiﬁed (Nox1–5, Duox-1 and −2).
These are transmembrane proteins which facilitate the transfer of an
electron from NADPH within the cell cytosol, via coordinated heme
groups to reduce molecular oxygen (O2) to superoxide (O2-) on the
opposite side of the membrane [1,2]. Despite the apparent similarity in
function of the different isoforms at the biochemical level, differentfamily members display distinct quantitative and qualitative cellular
expression patterns, suggesting distinct functions [1–3]. In addition, in
cells inwhichmore than one isoform is expressed, the different isoforms
typically display contrasting intracellular localisation patterns, again
indicating speciﬁc functions [4–7].
The activities of different Nox isoforms are subject to very different
modes of regulation. Thus Nox1 and Nox2 are acutely regulated by
posttranslational mechanisms such as the phosphorylation of regulato-
ry subunits induced by the activities of agonists. [2,3]. By contrast the
activity of Nox4 is constitutive and does not require agonist stimulation,
or the association of regulatory proteins other than p22phox[8–10].
Consequently its activity is dependent on its level of protein expression,
and the ROS it generates is inducible at the level of gene transcription
rather than acute, posttranslational mechanisms [11]. Furthermore,
many groups have reported that the ROS generated by the different
isoforms may differ. Thus while Nox2 is known to generate O2-, the ROS
generated by Nox4 have only been convincingly demonstrated using
detection systems speciﬁc to H2O2 [9,11–13].
Within cardiomyocytes, Nox2andNox4are coexpressed, yet the two
isoforms exhibit contrasting patterns of intracellular localisation.
Whereas Nox2 is primarily located at the cell membrane [14], Nox4
displays a perinuclear and ER-associated expression pattern [10,15].
Several studies in mouse models of impaired Nox2 activity have
demonstrated that Nox2-generated ROS are involved in the develop-
ment and progression of cardiac hypertrophy, and contractile dysfunc-
tion induced by angiotensin II, pressure overload, or myocardial
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effects of Nox2 activity, Nox4-generated ROSwere shown, in both gain-
of-function and loss-of-function mouse models, to be beneﬁcial during
cardiac remodelling after load-induced stress by enhancing myocardial
capillary density and functional cardiac compensation [10]. Endogenous
Nox4 expression increases in cardiomyocyes in vivo as a response to
pathological stresses of pressure overload or myocardial infarction, and
in vitro following hypoxic insult. This increase acts to trigger adaptive
stress response(s), including an increase in angiogenesis, through the
activation of hypoxia inducible factor 1 [10]. Nox4 has also been
suggested to be important in cardiomyocyte differentiation, as speciﬁc
depletion of Nox4 expression in embryonic stem cells (ESCs) resulted in
a reduction in the efﬁciency of ESC differentiation into beating EBs [22].
The involvement of p38 mitogen activated protein kinase (MAPK) in
driving the cardiogenic pathway, downstream of Nox4, was also
demonstrated in this study.
The precise molecular targets of oxidation, which mediate the
cellular response(s) to increased ROS production by NADPH oxidases
in cardiomyocytes and other cells, remain unclear. The most likely
mechanism by which NADPH oxidase-generated ROS regulate
cellular function is through the reversible thiol oxidation of reactive
cysteine residues within regulatory proteins. Potential targets of ROS
modiﬁcation include protein tyrosine phosphatases (PTPs), protein
tyrosine kinases, ion channels, and transcription factors [1,23]. One
potential target and effector of ROS signaling is the cap ‘n’ collar basic
leucine zipper transcription factor, Nrf2. Nrf2 acts as a positive
transcriptional regulator of a battery of genes involved in antioxidant
and xenobiotic defense systems [24,25]. Under normal, highly
reducing cellular conditions Nrf2 is sequestered in the cytoplasm
by associationwith the Kelch-like ECH-associated protein 1 (KEAP 1),
and targeted for ubiquitination and proteasomal degradation [26].
However under conditions of increased ROS production, oxidation of
critical cysteine residues within KEAP 1 triggers its dissociation from
Nrf2, preventing Nrf2 degradation and allowing its translocation into
the nucleus [27]. Within the nucleus Nrf2 can bind to cis-acting
elements called antioxidant-responsive elements (AREs) or electro-
phile-responsive elements (EpREs)within the promoters of its target
genes to effect their upregulation [28,29]. Recently it has additionally
been demonstrated that Nrf2 itself is a potential direct target of
oxidation, and that its nuclear distribution and consequent activity
can be regulated through modiﬁcation of speciﬁc cysteine residues
by oxidation [30]. A number of studies have implicated ROS
generated by NADPH oxidases in the activation of Nrf2-dependent
pathways [31–35]. However all of these studies have relied on
ablating NADPH oxidase activity by the use of pharmacological
inhibitors, and direct genetic evidence for the involvement of any
speciﬁc Nox isoform has so far been lacking.
In this study we aimed to identify downstream targets of Nox4-
derived ROS in the heart in vivo. We have made use of a cardiac-
speciﬁc Nox4 overexpressing transgenic (tg) mouse in which
expression of the Nox4 transgene is driven by the αMHC promoter
[10]. We have previously shown that Nox4 expression levels are
signiﬁcantly higher in the late stage fetal heart than in the normal
adult heart [10]. Here we compare the effects of this decline in Nox4
levels after birth with the αMHC-driven increase in Nox4 expression
that occurs at this time in the tg mice. We demonstrate that this
increased expression of Nox4 in tg mice results in a highly signiﬁcant
upregulation in the expression of Nrf2-regulated genes, including
those involved in glutathione (GSH) biosynthesis and recycling. In
addition the early postnatal hearts of the transgenic mice display
higher levels of reduced GSH and a higher ratio of GSH/GS-SG than
wild-type littermate controls. The involvement of Nrf2 in this
phenotype was conﬁrmed in experiments where it was ablated in
an Nrf2 null genetic background. These data represent the ﬁrst
deﬁnitive genetic demonstration of the activation of the Nrf2-
mediated antioxidant pathway(s) by Nox4-derived ROS [36].Materials and methods
Transgenic mice
Cardiomyocyte-targeted Nox4-transgenic mice have been de-
scribed previously [10]. Lines were backcrossed N10 generations
onto a C57BL/6 background. Nrf2 null-mice have been described
previously [37].
mRNA extraction and microarray analyses
Total RNAwasextracted fromhomogenisedheart tissueusing the SV
total RNA isolation kit (Promega) according to the manufacturer's
instructions. RNA quality was assessed on an Agilent 2100 bioanalyser
and cRNA was prepared and hybridised as described previously [38].
Two Mouse Expression Arrays (Afﬁmetrix) each representing approx-
imately 23,000 transcripts were screened. Equivalent samples of pooled
RNAwas used from triplicate heart samples prepared from 2-week-old
Nox4-transgenic mouse hearts, or wild-type littermate controls (males
and females). Expression levels of transcripts were assessed using
statistical algorithms in the Microarray Analysis Suite 5.0 software
(Afﬁmetrix). Data were scaled to correct for variations in hybridisation
efﬁciency and laser power, etc. Only genes with a change in expression
(signal log ratio ≤ −1.0 or ≥ +1.0) between arrays were considered.
Genes known to be sex linked in their expression, such as genes
involved in X chromosome inactivation, were not included in the
analyses.
cDNA synthesis and Q-PCR
Total RNAwas reversed-transcribed, using random decamers, with
M-MLV RT (Promega) according to the manufacturer's protocol.
Control reactions, omitting the RT, were also performed in all cases.
Relative gene expression was quantiﬁed on an Applied Biosystems
7000 sequence detection system (Applied Biosystems, UK) using SYBR
Green and the comparative Ct method, with cytoskeletal β-actin levels
used for normalization, as described previously [38]. Forward (F) and
reverse (R) primers used to detect mouse transcripts were as follows
(all 5′-3′).
βactin F, CTGTCGAGTCGCGTCCACCC; R, ATGCCGGAGCCGTTGTCGAC;
Nox4 F, CCGGACAGTCCTGGCTTATC; R, TGCTTTTATCCAACAATCTTCTTTT;
GSTα2 F, GCTTGATGCCAGCCTTCTG; R, GGCTGCTGATTCTGCTCTTGA;
GCLC F, GTTATGGCTTTGAGTGCTGCAT; R, ATCACTCCCCAGCGACAATC;
Txnrd 1 F, GATGCACCAGGCAGCTTTG; R, TCTTCGACTTTCCAGCCATAGT;
HO 1 F, CAGCCCCACCAAGTTCAAA; R, TCAGGTGTCATCTCCAGAGTG;
NQO 1 F, GCCCGCATGCAGATCCT; R, GGTCTCCTCCCAGACGGTTT;
GSR F, TGGTAGGAAGCCCACCACAA; R, ATTTGGGTCCCGTCCAATG;
Nrf2 F, CTACTCCCAGGTTGCCCACA; R, CGACTCATGGTCATCTACAAATGG.
Western blotting
Snap-frozen tissue was simultaneously homogenised and lysed in
hypotonic lysis buffer [50 mM Hepes, pH 7.4, 10 mM KCl, 5 mM EDTA,
5 mM EGTA, 2 mM MgCl2, 2 mM DTT, 0.1% CHAPS, and protease
inhibitor cocktail (Sigma)]. Protein concentrations were determined by
Bradford assay to ensure equal protein loading and samples (20–50 μg)
were then denatured in Laemmli loading buffer. Proteins were
separated on either an 8 or 10% SDS-PAGE gel and transferred to PVDF
membrane. Membranes were probed with antibodies against peroxir-
edoxin-SO3 (Abfrontier), Nox2 (BD Transduction), and Nox4 [4]. Blots
were probed for β-actin (Sigma) as a loading control. Protein bands
were visualised using Amersham Biosciences ECL Western blotting
detection reagent (GE Healthcare) according to the manufacturer's
instructions.
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Nuclear extracts were prepared from freshly isolatedwt and Nox4-
overexpressing tg mice hearts using the NE-PER Nuclear and
Cytoplasmic Extraction kit (Pierce Biotechnology) as per the manu-
facturer's recommendations. Protein concentrations were measured
by the Bradford assay and Western blot analysis of nuclear extracts
showed a purity of ~85%. Nrf2 DNA binding activity was assessed
using a TransAM Transcription Factor ELISA kit (Active Motif). The
assay consists of oligonucleotides encoding a consensus antioxidant
response element (ARE) immobilised to a 96-well plate to which Nrf2
binds. Ten micrograms of nuclear extract was incubated in each well
in either the presence or the absence of competing consensus ARE-
oligonucleotide for 1 h, as per the manufacturer's instruction. A
primary antibody against Nrf2 followed by a horseradish peroxidase
(HRP)-conjugated secondary antibody allowed a colorimetric readout
of Nrf2 binding activity, which is expressed as OD450 nm±SD.
Immunocytochemistry
Immunocytochemistry was performed on 6-μm sections, cut from
parafﬁn-embedded wt and tg hearts from 9-day-old mouse pups.
Primary antibodies against KEAP 1 (Cell Signaling Technology, Cat. No.
4617) and Nrf2 (Santa Cruz Biotechnology, Cat. No. sc-722) were both
used at a dilution of 1:50. Biotinylated-secondary antibodies were
detected using a peroxidase-based immunostaining kit (Vectastainβ-Actin








Fig. 1. Expression of Nox4 in wt and tg hearts. (A) Q-PCR analyses of relative expression of end
analyses of Nox4 transgene expression inDay 0, 1 week, and 2 weekpostnatal hearts. Hearts sam
β-actin, and are plotted as arbitary units (AU). (C) Nox4 protein levels in 15 daywt and tg embry
at 2 days and 2 weeks after birth, as indicated (15 μg protein loaded in each case). (E) Analyses
(15 μg protein loaded in each case). ** Pb0.01.Elite ABC kit, Vector Laboratories) and diaminobenzidine (ImmPACT
DAB; Vector Laboratories). Sections were counterstained with
hematoxylin.Glutathione assays
Freshly isolated heart tissue was snap-frozen in liquid N2, and
subsequently stored at −80 °C. Samples were homogenised in phos-
phate-buffered saline containing 2 mM EDTA, at a concentration of
20 mg tissue/ml PBS. GSH assays were performed using the GSH-Glo
assay kit (Promega), exactly as described by the manufacturer. To
measure total glutathione levels (GSH + GS-SG), extracts (50 μl) were
preincubated in a ﬁnal concentration of 1 mM tris(2-carboxyethyl)
phosphine hydrochloride (TCEP; Sigma), for 30 min at room tempera-
ture, before proceeding with the assay. Frommeasurements of the total
and reduced glutathione levels, the levels of oxidised GS-SG (total-
reduced) and the glutathione redox couple (GSH/GS-SG) were
calculated.Statistical analyses
Data are expressed as mean±SEM. Comparisons between wt and
tg cohorts or measurements at different time points were made by






ogenous Nox4mRNA, in postnatal hearts at birth (day 0), 1 week, and 2 weeks. (B) Q-PCR
ples from3 littermate animalswere analysed in all cases. Values are shownnormalised to
onic hearts (amounts of protein loaded as inducated); (D) Nox4 protein levels in tg hearts,
of hyperoxidised Prdx in wt and tg littermate controls at 2 weeks after birth, as indicated
Table 1
Nrf2-regulated genes, found to be upregulated by Nox4 in a microarray screen.
Gene name GenBank Accession Log2 ratio
aldo keto reductase AK009462 0.3
aldehyde oxidase 1 NM_009676 1.0
activating transcription factor 4 AV314773 1.2
chaperone subunit 7 NM_007638 1.0
dnaJ (Hsp40) homolog, subfamily A, member 2 C77509 0.4
dnaJ (Hsp40) homolog, subfamily A, member 3 NM_023646 0.4
dnaJ (Hsp40) homolog, subfamily B, member 9 NM_013760 0.7
dnaJ (Hsp40) homolog, subfamily B, member 11 AK010861 0.4
dnaJ (Hsp40) homolog, subfamily C, member 3 BC013766 0.2
epoxide hydrolase 1 NM_010145 1.1
ferritin light chain 2 NM_008049 0.6
glutamate-cysteine ligase, catalytic subunit, BC019374 0.9
glutamate-cysteine ligase , modiﬁer subunit NM_008129 0.8
glutathione-S-transferase, alpha 2 NM_008182 5.5
glutathione-S-transferase, alpha 4 NM_010357 0.9
glutathione-S-transferase, mu 2 NM_008183 0.8
glutathione S-transferase, mu 1 NM_010358 0.8
glutathione S-transferase omega 1 NM_010362 0.7
glutathione reductase 1 NM_010344 0.6
heme oxygenase 1 NM_010442 0.4
herpud 1 AI835088 0.5
microsomal glutathione S-transferase 1 BC009155 1.1
NAD(P)H dehydrogenase, quinone 1 AV158882 1.4
peroxiredoxin 1 NM_011034 0.3
related RAS viral (r-ras) oncogene homolog 2 BE200500 0.5
sequestosome 1 BM232298 0.8
small stress protein-like protein (HSP22) AF250139 0.6
superoxide dismutase 1 BC002066 0.3
thioredoxin NM_011660 0.4




valosin containing protein AI195225 0.2
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Expression of Nox4 in the postnatal heart
We have demonstrated previously that Nox4 mRNA expression is
much higher in the late-staged fetal heart than in the adult heart [10].
We here further investigated the pattern of endogenous Nox4 mRNA
expression in mouse hearts immediately after birth, and at 1 week
and 2 weeks of age. We found a sharp decline in expression
immediately after birth, and in particular during the ﬁrst week of
life (Fig. 1A). Recently we reported the generation of a tg mouse line,
which expresses Nox4 speciﬁcally in cardiomyocytes, under the
control of the mouse αMHC promoter [10]. In rodents, expression of
βMHCwithin the ventricles predominates during embryonic and fetal
development while αMHC is strongly upregulated from birth [39].
Accordingly Nox4mRNA levels increase sharply during the immediate
postnatal period in tg mice (Fig. 1B). At the protein level, endogenous
Nox4 can be detected in the late stage (15 day) wt embryo heart, and
transgenic Nox4 expression at this stage (allowing for the differences
in amounts of protein loaded) was estimated to be approximately 70-
fold higher (Fig. 1C). This is in broad agreement with measurements
of relative levels of Nox4 mRNA in wt and tg hearts at this stage (data
not shown). After birth, the decline in the levels of normal Nox4
expression (Fig. 1A and [10]) precludes its detection by Western
blotting in our postnatal wt animals. By contrast, transgenic Nox4
protein expression increases sharply after birth, in linewith themRNA
expression pattern (Fig. 1D). Thus Nox4 in these tg mice is increasing
at a time when the normal endogenous levels decrease.
We reported previously that extracellular H2O2 in tg mouse
myocardium was increased by approximately 30% [10]. We have
further analysed the intracellular production of H2O2in situ, using an
antibody speciﬁc to the hyperoxidised active site of four peroxir-
edoxin isoforms (Prdx 1–4) in which the thiol group within the active
site is oxidized to either a sulphinic (SO2) or (irreversibly) to a
sulphonic (SO3) group. Previous reports have demonstrated that high
levels of hyperoxidised Prdx are observed after ex vivo treatment of
heart tissue with H2O2[40]. As shown in Fig. 1E, a signiﬁcant increase
in levels of hyperoxidised Prdx was observed in 2-week-old tg mouse
hearts, compared to wt controls, consistent with the production of
intracellular H2O2.
Microarray analyses of Nox4-overexpressing hearts
To elucidate the molecular targets of Nox4-generated ROS, we
performed a microarray screen, in which we compared the transcrip-
tomes of 2-week-old transgenic and wild-type hearts. At this point, the
signiﬁcant changes in Nox4 expression in tg compared to wt mice, and
consequent ROS generation, would be likely to effect dynamic switches
in signaling pathways and downstream transcriptional programs. We
screened two Mouse Expression Set 430A chips (Affymetrix), using
pooled cRNA prepared from equivalent amounts of either 3 tg or 3 wt
hearts, and identiﬁed 174 characterised, unique genes whose expres-
sionwas changed at least 2-fold as a result of increasedNox4expression.
Of these, 70 genes were upregulated and 104 genes were down-
regulated (see Supplementary Data for a list of upregulated genes). It
should be noted, however, that the use of only one chip per sample
precludes any statistical analyses to evaluate the signiﬁcance of changes
in gene expression of less than 2-fold. Thus the lists of genes presented
here may underestimate the downstream transcriptional targets of
Nox4 signaling. These microarray data have been submitted to the EBI
ArrayExpress database, and can be accessed at http://www.ebi.ac.uk/
arrayexpress, Accession Number E-MEXP-3161.
The differentially regulated genes identiﬁedwere analysed using the
Ingenuity Systems Pathway Analysis Software (http://www.ingenuity.
com/), which identiﬁed cell proliferation and growth as the cellular
function which had been most affected by Nox4 overexpression(P=8.10×10-9). In addition the Nrf2-regulated antioxidant response
pathway was identiﬁed by this application as a canonical pathway that
was highly signiﬁcantly changed (P=2.27×10-6). Thus a signiﬁcant
upregulation was observed in the expression of several genes known to
be positively regulated by Nrf2, including glutathione S-transferase α2
(GSTα2), thioredoxin reductase 1 (Txnrd1), and NAD(P)H dehydroge-
nase, quinone1 (NQO1). Inaddition, the expression levels ofmanyother
known target genes of Nrf2 activation, such as heme oxygenase (HO 1),
glutamate-cysteine ligase, catalytic subunit (GCLC), and glutathione
reductase (GSR), were also increased, although less than 2-fold
(Table 1). We veriﬁed the results of the microarray by individual Q-
PCR analyses of multiple RNAs isolated from 2-week-old wt and tg
mouse hearts (Fig. 2). In agreement with our microarray data, the most
signiﬁcant change in expression was observed in the case of GSTα2,
which was upregulated approximately 40-fold (Fig. 2A), while more
modest increases in mRNA levels of other genes were apparent (HO 1,
NQO1, GCLC, Txnrd1, GSR; Figs. 2B–F).
We also assayed Nrf2 mRNA levels and DNA binding activity in
these hearts. As shown in Fig. 2G, the levels of Nrf2 mRNA were
equivalent in the wt and tg groups. However an ELISA-based Nrf2
binding assay demonstrated signiﬁcantly higher levels of binding to
an immobilised consensus ARE in nuclear extracts prepared from tg
compared to wt hearts (Fig. 2H).
To further validate these ﬁndings we performed immunostaining
on heart sections of wt and tg hearts using antibodies to KEAP 1 or
Nrf2. KEAP 1 stainingwas cytoplasmic andwasmarkedly higher in the
wt, rather than tg hearts (Figs. 3A and B). By contrast Nrf2 staining
was clearly localized strongly to the nucleus, speciﬁcally in the tg
heart sections (Figs. 3C and D).
These ﬁndings are consistent with the hypothesis that Nox4-
generated ROS may upregulate Nrf2 activity by the posttranslational
oxidative modiﬁcation of Keap 1, which results in its degradation and






Fig. 2. Expression ofNrf2-regulated genes inNox4 tgmouse hearts. (A–G)Q-PCR analyses of Nrf2-regulated genes, andNrf2 itself in 2 week postnatal tg andwtmouse hearts as indicated.
Triplicate tg andwt littermate controlswere analysed, and relative expression is shown normalised toβ-actin in all cases, plotted as arbitary units (AU). (H) Analyses of binding activity of
Nrf2 in wt and tg littermate mouse hearts. In both cases binding to the immobilised Nrf2 oligonucleotide is ablated by self-competition (+wt Nrf2 oligo). ** Pb0.01, * Pb0.05.
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Some of the target genes of Nrf2 activation are involved in both the
biosynthesis of GSH, such as GCLC [41], and its redox recyling, such as
GSR [42]. Thus Nrf2 has been shown to be a critical regulator of boththe level of GSHwithin the cell and the ratio of oxidised:reduced GSH,
i.e., the GSH/GS-SG redox couple. We therefore measured both the
total level of GSH (i.e., GSH + GS-SG) and the level of reduced GSH
alone, in the hearts of 12-day-old transgenic mouse and their





A                         B 
C D
Fig. 3. Expression of KEAP 1 and Nrf2 in Nox4 tg mouse hearts. Immunocytochemistry showing stronger cytoplasmic expression of KEAP 1 in wt (A) compared to Nox4 tg (B) hearts
(brown stain). Increased nuclear localisation of Nrf2 expression is seen in tg (D) compared to wt (C) hearts (brown stain). Arrows depict strong nuclear expression of Nrf2 that is not
apparent in wt sections. Nucleii are stained with hematoxylin (violet) in all panels. Scale bar: 10 μm.
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point close to 2 weeks was chosen in order to maximise the effects of
Nox4 signaling apparent in the hearts. As shown in Fig. 4A, the total
levels of glutathione (GSH+GS-SG)were signiﬁcantly elevated in the
tg hearts, and this increase was predominantly due to the increase in
the level of reduced (GSH), rather than oxidised (GS-SG), as reﬂected
in the increased GSH:GS-SG ratio (Figs. 4B–D). Because it is desirable,
where possible, to use littermate animals for these studies, bothmales
and females were used. Sex differences in the levels of GSH have been
demonstrated for aging mice, although in most tissues GSH levels in
young mice were reported to be equivalent [43]. We compared GSH
levels in male and female wt and tg mice aged 12 days, but found
levels to be equivalent between males and females in both the wt and
the tg groups (Fig. 4E). To further conﬁrm that the difference in GSH
levels observedwas due to Nox4 overexpression, we studied a second,
independent αMHC-Nox4 tg mouse line and found similar results
(Fig. 4F), thereby excluding an integration site effect.
We alsomeasured the levels of GSH in the hearts of normal wt mice
in a postnatal time course. As seen in Fig. 4G, GSH levels were found to
decrease markedly during the ﬁrst 2 weeks of life, in parallel with the
observed decrease in expression of endogenous Nox4 (Fig. 1A).
Ablationof effects ofNox4overexpression inanNrf2-null genetic background
To conﬁrm that the changes observed in the expression of known
Nrf2-regulated genes on overexpression of Nox4 were, indeed, a
consequence of the activation of Nrf2, we crossed the Nox4 tg mice
onto an Nrf2-null genetic background [37]. The Nrf2-null homozygotic
micewere foundnot tobe fertile; thus,we set up crosses between cohorts
of heterozygous Nrf2−/+ male mice, and heterozygous Nrf2−/+
females which also carried the Nox4 transgene. The offspring of these
crosseswere genotyped, and age-matched animals from several differentlitters (males and females) were pooled from the four groups of interest:
Nrf2−/− and Nrf2+/+ mice that did, or did not, carry the Nox4
transgene in each case. We ﬁrst assessed by Q-PCR the mRNA levels of a
subset of the putative Nrf2-regulated genes, which were shown
previously to be upregulated by ectopic Nox4 expression. As in the
originalmicroarray analyses, RNAwas isolated fromhearts from2-week-
oldmice for this study. As shown in Fig. 5, the increase in transcription on
ectopicNox4expressionof all the genes tested (GSTα2,NQO1, TrxR1, and
GCLC) was ablated in the Nrf2-null background. We additionally
measured the levels of GSH in samples of the same hearts used to
prepare RNA, and again the increase in GSH, apparent in the Nox4tg
hearts, was not seen in mice lacking Nrf2 (Fig. 5E). These data are
therefore consistent with Nox4-generated ROS both effecting changes in
the transcription of antioxidant and phase II detoxifying enzymes and
mediating regulation of the GSH cellular redox state within the heart by
redox control of Nrf2.
Activation of Nrf2 is not apparent in Nox2-overexpressing mice
Previous studies using the ﬂavoprotein inhibitor, diphenylene
iodonium chloride (DPI), have implicated NADPH oxidase(s) in the
activation of Nrf2 in various in vitro settings, but do not inform which
speciﬁc Nox isoformmight be involved [31–35]. To determine whether
the ability to activate Nrf2 in cardiomyocytes in vivo is speciﬁc to Nox4,
we analysed a transgenicmouse line inwhichNox2 (themain otherNox
isoform expressed in cardiomyocytes) is overexpressed speciﬁcally in
cardiomyocyes under the regulation of the mouse MLC-2v promoter.
These Nox2 tg mice were shown to express high levels of Nox2 mRNA
and protein in the postnatal heart (manuscript in preparation). We
assessed the mRNA levels of the two Nrf2-regulated genes which were
shown to be most signiﬁcantly increased in the Nox4 tg mouse hearts,





Fig. 4. Glutathione levels and GSH/GS-SG redox couple in Nox4 tg hearts. Levels of (A) total (GSH + GS-SG), (B) reduced (GSH), and (C) oxidised (GS-SG) glutathione in 12 day
postnatal Nox4 tg and littermate wt hearts (males and females). (D) Ratio of GSH/GS-SG in these hearts. Cohorts of 3 tg and 3wt littermate controls were used for this study. (E) GSH
levels in hearts of tg and wt, males and females, from 2 pooled 12 day litters. Cohorts of 3 animals were assessed in each case. (F) GSH levels in 3 tg and 3 wt littermate control hearts
of 2 week postnatal mice of a second Nox4 tg line. (G) Time course of endogenous GSH levels in hearts of wt mice. Three littermate samples were assessed at birth (Day 0), 1 week,
and 2 weeks. Results are plotted on an arbitrary scale of relative light units (RLU) ** Pb0.01, * Pb0.05.
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found to be unchanged in 2-week-old Nox2 tg mice compared to wt
littermate controls (Fig. 6C).
Discussion
Activation of Nrf2-dependent transcription by Nox4 in cardiomyocytes
There is compelling evidence to suggest that ROS generated by
Nox4 functions in many different cell types to determine cell fate andfunction [22,44–48]. Nox4 produces ROS constitutively and conse-
quently its activity reﬂects its level of expression [11]. Signiﬁcant
changes in intracellular Nox4 mRNA and protein levels are therefore
likely to signal regulatory cellular physiological processes. However,
the effects of Nox4-dependent signaling appear highly cell-type and/
or developmental-stage speciﬁc. Thus in cultured vascular smooth
muscle cells (VSMCs) in vitro, increased Nox4 expression can act to
promote either cellular differentiation or proliferation, dependent on
cell culture conditions [44,47]. In preadipocytes and cardiac ﬁbro-




Fig. 5. Upregulation of Nrf2-regulated genes and GSH levels is ablated in an nrf2-null genetic background. (A–D) Q-PCR analyses of Nrf2-regulated genes in 2 week postnatal Nox4 tg
and wt hearts in a normal (black bars) or Nrf2-null genetic background (gray bars), as indicated. Cohorts of 3 age-matched mice (males and females) were used for this study, from
pooled litters, and relative expression is shown normalised to β-actin in all cases, plotted as arbitary units (AU). (E) GSH levels in the same cohorts of mice assessed in A–D, plotted on
an arbitrary scale of relative light units (RLU). ** Pb0.01, * Pb0.05 in all cases.
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increased Nox4 expression in endothelial cells was shown to promote
a more proliferative phenotype [49]. It is therefore of signiﬁcance that
in the microarray that we performed here, the cellular function that
was identiﬁed to be most signiﬁcantly altered as a result of Nox4
overexpression in cardiomyocytes was cell growth and proliferation.
The phenotypic consequences of this altered gene expression are,
however, beyond the scope of this paper. It should be noted, however,
that Nox4-null animals have been generated and do not display any
basal phenotype [10]. This suggests that Nox4 does not play a critical,
nonredundant role in cellular differentiation. Future experiments
involving inducible and/or stage-speciﬁc cardiac ablation of Nox4
during embryogenesis are therefore needed to inform its normal
function(s) in cardiomyocyte cell differentiation and growth.
The precise molecular mechanisms which underlie these Nox4-
dependent cellular functions, however, are largely unknown. Inparticular the targets of oxidation of the ROS, generated by Nox4,
need to be elucidated. Recently, thiol modiﬁcation and consequent
inhibition of two protein phosphatises, PTP1B andMAPK phosphatase
MKP-1, dependent on Nox4-generated ROS, have been demonstrated
in endothelial cells and ﬁbroblasts respectively [50,51]. We demon-
strate here the ability of Nox4-generated ROS to activate the Nrf2-
dependent pathway in cardiomyocytes in vivo. Nrf2 is a positive
regulator of a plethora of genes involved in antioxidant and xenobiotic
defense. These include the phase II detoxifying enzymes, such as
glutathione S-transferases (GSTs) and NAD(P)H:oxioreductase 1
(NQO 1), enzymes involved in the biosynthesis and recycling of
glutathione, such as glutamate-cysteine ligase catalytic subunit
(GCLC) and glutathione reductase (GSR), and antioxidants such as
thioredoxin reductase 1(Txnrd1) and heme oxygenase (HO 1)
[24,42,52]. Our microarray screen demonstrated the expression of
Nrf2-dependent genes to be highly signiﬁcantly upregulated by
AC
B
Fig. 6. Nox2 overexpression does not activate Nrf2. (A, B) Q-PCR analyses of Nrf2-
regulated genes in Nox2 tg, Nox4 tg, and wt mouse hearts as indicated. Triplicate heart
samples were analysed from adult Nox2 tg and age-matched wt control animals, and
2 week Nox4 tg mice. Relative expression is shown normalised to β-actin in all cases,
plotted as arbitary units (AU). ** Pb0.01. C; GSH levels in cohorts of 4 approx 6-week-
old Nox2 tg mouse hearts and wt littermate controls (males and females) plotted on an
arbitrary scale of relative light units (RLU).
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upregulation was completely ablated in an Nrf2-null genetic back-
ground, demonstrating deﬁnitively the involvement of Nrf2 in the
molecular pathway.
There have been several reports describing distinct mechanisms of
activation of Nrf2, most (but not all) of which appear to be redox-
mediated [27,53–57]. In vitro and in vivo, the expression of antioxidant
and detoxiﬁcation enzymes regulated by Nrf2 has been shown to be
induced by a variety of chemical agents which act as electrophiles,
including diphenols, quinones, isothiocyanates, arsenicals, and heavy
metals [58]. Both Nrf2 itself and KEAP1, which acts as a negative
regulator ofNrf2 activity, are susceptible to oxidative thiolmodiﬁcations
of reactive cysteines which regulate their functions [27,30], and are
therefore potential targets of NADPH oxidase-generated ROS. In
addition phoshorylation of Nrf2 by protein kinase C has been shown
to facilitate the dissociation of Nrf2 from KEAP1; a process which may
also be redox regulated [59]. Our data are consistent with activation of
Nrf2 by mechanism(s) involving oxidative posttranslational modiﬁca-
tion. Thus mRNA levels of Nrf2 were not altered in the Nox4 tg mice,
whereas the nuclear binding activity of Nrf2 was signiﬁcantly increased
by Nox4 overexpression. Several previous reports have suggested thatROS generated by NADPH oxidases can activate Nrf2 in vitro[31–35].
However, all of these studies have been based on the inhibition of the
oxidase activity by nonspeciﬁc agents such asDPI and apocynin, and the
speciﬁcity of both these reagents has been questioned [60]. The data
presented here represent the ﬁrst direct genetic evidence that ROS
generated in situ by an NADPH oxidase, i.e., Nox4, can activate Nrf2.
It is now clear that different Nox isoforms can effect distinct
signaling responses in cells in which they are coexpressed [4,6,7]. This
likely results from differences in the intracellular localisation of the
Nox isoforms, the levels and species of ROS generated, and the
duration of production of the ROS. By contrast to Nox4, cardiac-
speciﬁc overexpression of Nox2 did not result in activation of Nrf2 in
our Nox2 tg mice. One potential explanation for this difference is that
constitutive, continuous production of ROS is required to modulate
Nrf2.
In addition to Nrf2-regulated genes, we also found many other
genes that were upregulated in the Nox4 tg hearts, which remained
altered in the Nrf2-null genetic background (data not shown). These
results suggest that Nox4-derived ROS can regulate other pathways
distinct from those controlled by Nrf2.
Regulation of GSH levels by Nox4 during cellular differentiation
Nrf2 has been suggested previously to be a key regulator of GSH
redox in a variety of cellular settings [61,62]. We show here that in
cardiomyocytes Nox4-generated ROS regulates both the level and the
redox state of GSH through modulation of Nrf2 activity. In addition to
its role as part of an integrated antioxidant system, the GSH redox
state per se is known to be a critical regulator of skeletal muscle
differentiation [63]. In addition, endogenous H2O2 was shown to
regulate the GSH redox state during skeletal muscle cell differenti-
ation in vitro, although the source of the ROS was not identiﬁed [61].
Nonetheless, the H2O2 produced during the differentiation process
was shown to act in a strikingly similar fashion to the ROS generated
in the Nox4 tg mouse hearts, described here. Namely the H2O2 acted
via Nrf2 to mediate the cellular GSH redox state by activation of the
GSH biosynthetic and recycling enzmes, GCLC and GSR. The authors
further demonstrated the involvement of phosphatidylinositol 3-
kinase in the activation of Nrf2, downstream of the ROS production.
Nox4 activity has been demonstrated to be critical for efﬁcient
cardiomyocyte differentiation, in vitro. Our data may therefore
suggest that modulation of GSH levels through regulation of Nrf2
may be an important mechanism which underlies the emerging role
of Nox4 in cellular differentiation [22,44–48].
Role of Nox4 in cardiomyocytes
Diverse functions, including gene expression, cell-cycle progres-
sion, apoptosis, and metabolism, have also been suggested to be
regulated by the intracellular GSH redox state [64–66]. Few studies
have so far focused on the speciﬁc role of Nox4 with cardiomyocytes
in vivo. We found that GSH levels drop sharply in the postnatal heart,
concomitant with a decrease in Nox4 expression. During this time
cardiomyocytes undergo many complex changes in their physiology
as they adapt to the demands of their altered environment [67].
Therefore the regulation of GSH levels via Nrf2 to inﬂuence the
profound changes in cardiomyocyte proliferation, cell growth, and
metabolism that occur in the postnatal heart may be an important role
of Nox4.
A function for Nox4 in the adult heart has also been demonstrated
in that, as a response to pathophysiological stress, its expression is
increased and it effects an adaptive cardioprotective response [10].
Therefore higher levels of expression of Nox4 in cardiomyocytes
associate with a more fetal phenotype, that can be reactivated in the
adult heart as a response to stress [10,68]. Recently it has also been
suggested that Nrf2 is a mediator of this cardioprotective adaptive
214 A.C. Brewer et al. / Free Radical Biology & Medicine 51 (2011) 205–215response to hemodynamic stress [69], and again suggests that
activation of Nrf2 is a molecular mechanism underlying Nox4 function
in the cardiomyocyte.
Taken together, the results of this study suggest that Nox4 may be
an important regulator of GSH redox state in cardiomyocytes, through
the modulation of Nrf2 activity.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.freeradbiomed.2011.04.022.
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